Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 20,169 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multicenter Trial Clear all
Terminated Phase 4 Interventional Results available

A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease

NCT01597596
View directory record Official record
Conditions
Pompe Disease (Infantile-Onset), Glycogen Storage Disease Type II (GSD II), Glycogenosis 2, Acid Maltase Deficiency
Interventions
alglucosidase alfa
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 12 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Little Rock, Arkansas • Oakland, California • Gainsville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

NCT00513162
View directory record Official record
Conditions
Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
Interventions
Valproate, Etoposide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

NCT00000746
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1 SF-2, Env 2-3, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1994
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 8:27 AM EDT
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273
View directory record Official record
Conditions
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

NCT01644773
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, High-grade Glioma
Interventions
Crizotinib, Dasatinib
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

Moving Mindfully for Freezing in Parkinsons

NCT05309083
View directory record Official record
Conditions
Parkinson Disease, Freezing of Gait
Interventions
Mindfulness Based Walking Therapy (MBWT)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Jul 23, 2026, 8:27 AM EDT
Terminated Not applicable Interventional Results available

Acromegaly Combination Treatment Study

NCT01538966
View directory record Official record
Conditions
Acromegaly
Interventions
Pegvisomant, Octreotide LAR, Lanreotide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

Single Dose Pharmacokinetic (PK) Study

NCT03109756
View directory record Official record
Conditions
Angelman Syndrome, Fragile X Syndrome
Interventions
OV101
Drug
Lead sponsor
Healx AI
Industry
Eligibility
13 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
42
States / cities
Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329
View directory record Official record
Conditions
Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions
Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Effects of Vitamin D in Parkinson's Disease (PD)

NCT01119131
View directory record Official record
Conditions
Parkinson Disease, Accidental Falls
Interventions
Vitamin D3, calcium, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Jul 23, 2026, 8:27 AM EDT
Recruiting Not applicable Interventional

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Irradiation
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

NCT00264927
View directory record Official record
Conditions
Inappropriate ADH Syndrome, Hyponatremia
Interventions
SR121463B
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 9, 2008 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 2 Interventional

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

NCT00456586
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KW-6002 (istradefylline)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

Flexible Representation of Speech

NCT05209386
View directory record Official record
Conditions
Epilepsy
Interventions
Dimension-Based Statistical Learning
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 25 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 23, 2026, 8:27 AM EDT
Completed No phase listed Observational

Tryptophan Metabolism in Human Brain Tumors

NCT02367469
View directory record Official record
Conditions
Brain Tumors
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
13 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

NCT02197169
View directory record Official record
Conditions
Glioblastoma or Gliosarcoma
Interventions
Single intratumoral injection of DNX-2401, Interferon-gamma
Drug
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI)

NCT00446394
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia
Interventions
Resources and Activities for Life Long Independence (RALLI), Social Walking program (SW)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
70 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Jul 23, 2026, 8:27 AM EDT
Completed No phase listed Observational

Tele-diagnostics for Remote Parkinson's Monitoring

NCT01356056
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Kinesia HomeView
Device
Lead sponsor
Great Lakes NeuroTechnologies Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Jul 23, 2026, 8:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

NCT05972629
View directory record Official record
Conditions
Phenylketonuria
Interventions
SAR444836
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 23, 2026, 8:27 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jul 23, 2026, 8:27 AM EDT
Recruiting Not applicable Interventional

Telenutrition for Individuals With SCI

NCT05468437
View directory record Official record
Conditions
Spinal Cord Injuries, Obesity, Cardiometabolic Syndrome
Interventions
Telenutrition
Behavioral
Lead sponsor
Santa Clara Valley Health & Hospital System
Other
Eligibility
20 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 23, 2026, 8:27 AM EDT
Terminated Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

NCT03398837
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jul 23, 2026, 8:27 AM EDT
Completed Phase 4 Interventional Results available

A Carotid Stenting Boston Scientific Surveillance Program

NCT00741091
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Carotid WALLSTENT Monorail Endoprosthesis, FilterWire EZ™ System™
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
112
States / cities
Birmingham, Alabama • Fairhope, Alabama • Phoenix, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jul 23, 2026, 8:27 AM EDT